Bayer HealthCare

     2011

     2012

Employees: 55,700

Employees: 55,300
Change: -400, -0.7%

Revenues: €17.17B ($22.5B)

Revenues: €18.61B ($24.3B)

In terms of size of its workforce, Bayer HealthCare, which makes up about half the revenues of its parent, is one of the smaller players among the top 10. It ranked 10th in revenues and is ninth in number of employees, just above AstraZeneca ($AZN). The size of its workforce changed very little between 2011 and 2012. There were no major layoffs nor significant acquisitions.

But it did something few of the top 10 pharma players managed to do: It grew its prescription drug business last year. Roche ($RHHBY), Johnson & Johnson ($JNJ) and Abbott Laboratories ($ABT) were the only other Big Pharma companies to post higher pharma sales in 2012 than in 2011. On the other hand, it ranks in the bottom half of companies if compared by revenues per employee.

Overall, sales growth at Bayer HealthCare amounted to 8%, or 4.2%, adjusted for currency effects. Pharma sales and consumer health sales each grew at about the same rate, with pharma pitching in €10.8 billion and consumer health, €7.81 billion. You see, Bayer HealthCare is a bit of a mix. Its consumer health business is growing fast and now accounts for almost 42% of sales. And consumer health isn't just over-the-counter drugs. It includes animal health products and devices such as glucose meters, as well as its iconic Bayer Aspirin.

CEO Marijn Dekkers has pledged to grow Bayer HealthCare by 6% per year over the next several years. Much of that growth is expected to come from emerging markets, which now account for a third of its revenues and grew 8% while revenues in Europe were flat.

For more:
Bayer CEO touts Xarelto in Q3 pharma-sales growth
Bayer eyes 16% pharma growth on new meds

Bayer HealthCare
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.